Cd47 targeted therapies for the treatment of infectious disease
AssigneesThe Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Regents of the University of California
InventorsKipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
Claims19
A method of treating a subject for an intracellular pathogen infection, the method comprising:
- administering to the subject an anti-CD47 agent that reduces the binding of CD47 on an infected cell, to SIRPα on a phagocytic cell, at an effective dose for increasing the phagocytosis of the infected cell.
Dependencies are inferred from the claim text.